Verification of HE-based CTV in laryngeal and hypopharyngeal cancer using pan-cytokeratin

Clin Transl Radiat Oncol. 2018 Jul 11:12:21-27. doi: 10.1016/j.ctro.2018.07.003. eCollection 2018 Aug.

Abstract

Background: For accurate target definition, we determined margins for the clinical target volume (CTV) for laryngeal and hypopharyngeal cancer in computed tomography (CT, 4.3 mm), magnetic resonance imaging (MR, 6.1 mm) and fluorodeoxyglucose (FDG)-positron emission tomography (PET, 5.2 mm). Previously, we used Hematoxylin-eosin (HE) stained whole-mount sections of total laryngectomy specimens as gold standard to define CTV margins. In the present study, we verified the HE-based tumor delineation with staining for pan-cytokeratin, specific for squamous cell carcinoma.

Methods: Twenty-seven patients with a T3/T4 laryngeal hypopharyngeal tumor were included. From each patient, a total laryngectomy specimen was obtained. Four subsequent 3-mm thick slices containing tumor were selected of which 4-µm thick whole-mount sections were obtained and stained with HE and for pan-cytokeratin CK-AE1/3. Tumors were microscopically delineated on both sections by an experienced head-and-neck pathologist. Tumor delineations were compared using the conformity index (CI) and the distance between both contours.

Results: The CI between HE-based and CK-AE1/3-based tumor delineations was 0.87. The maximum and 95th percentile (p95) extent of the HE-based tumor delineations from the CK-AE1/3-based tumor delineations were 1.7 mm and 0.7 mm, respectively. The maximum and p95 extent of the CK-AE1/3-based tumor delineations from the HE-based tumor delineations was 1.9 mm and 0.8 mm, respectively.

Conclusions: Histopathological assessment of tumor outline on standard HE-stained sections is comparable to microscopic tumor extent based on squamous cell specific pan-cytokeratin staining. Therefore, CTV margins based on HE based tumor contour will be adequate.

Keywords: CI, conformity index; CK-AE1/3, cytokeratin AE1/3 antibodies; CT, computed tomography; CTV, clinical target volume; DAB, diaminobenzidine; FDG-PET, fluoro-deoxyglucose positron emission tomography; GTV, gross tumor volume; HE; HE, hematoxylin-eosin; HIER, heat-induced epitope retrieval; Head and neck; Histopathology; MRI, magnetic resonance imaging; PBS, phosphate-buffered saline; Pan-cytokeratin; SCC, squamous cell carcinoma; Squamous cell carcinoma; TLE, total laryngectomy; TME, tumor microenvironment; Target definition; p95, 95th percentile.